Holen Sie sich die Stockscreener-App
3.03
0.33%
0.010
Schlusskurs vom Vortag:
$3.02
Offen:
$3.03
24-Stunden-Volumen:
5,943
Relative Volume:
0.04
Marktkapitalisierung:
$52.96M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.05M
KGV:
-1.3527
EPS:
-2.24
Netto-Cashflow:
$-17.78M
1W Leistung:
-0.98%
1M Leistung:
-4.42%
6M Leistung:
-40.24%
1J Leistung:
-40.59%
1-Tages-Spanne:
$3.0111
$3.15
1-Wochen-Bereich:
$2.90
$3.22
52-Wochen-Spanne:
$2.45
$6.97
Envveno Medical Corporation Stock (NVNO) Company Profile
Firmenname
Envveno Medical Corporation
Sektor
Branche
Telefon
949-261-2900
Adresse
70 DOPPLER, IRVINE
Vergleichen Sie NVNO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corporation
|
3.04 | 52.96M | 0 | -24.05M | -17.78M | -2.15 |
|
ABT
Abbott Laboratories
|
113.64 | 196.18B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
359.38 | 137.26B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
89.67 | 131.64B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
80.33 | 102.43B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
72.96 | 43.66B | 6.60B | 4.16B | 490.10M | 6.93 |
Envveno Medical Corporation Aktie (NVNO) Neueste Nachrichten
enVVeno Medical Corporation (NASDAQ:NVNO) Director Acquires $15,660.00 in Stock - MarketBeat
Insider Buying: Sanjay Shrivastava Acquires Shares in enVVeno Me - GuruFocus.com
Envveno Medical's director Sanjay Shrivastava buys $15,660 in stock - Investing.com
Insider Buying: Matthew Jenusaitis Acquires 9,620 Shares of enVV - GuruFocus.com
Envveno medical director Matthew Jenusaitis buys $24,338 in stock By Investing.com - Investing.com Nigeria
Envveno medical director Matthew Jenusaitis buys $24,338 in stock - Investing.com India
Critical Survey: enVVeno Medical (NASDAQ:NVNO) versus Profound Medical (NASDAQ:PROF) - Defense World
NVNO stock touches 52-week low at $2.5 amid market challenges By Investing.com - Investing.com South Africa
NVNO stock touches 52-week low at $2.5 amid market challenges - Investing.com
Envveno Medical CEO Robert Berman acquires $30,599 in stock By Investing.com - Investing.com Australia
CEO Robert Berman Increases Stake in enVVeno Medical Corp with R - GuruFocus.com
Envveno Medical CEO Robert Berman acquires $30,599 in stock - Investing.com
enVVeno Medical completes final wave of implants in pre-clinical GLP study - TipRanks
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe - AccessWire
enVVeno Medical Completes Key Pre-Clinical Study for Revolutionary Venous Valve, Advances FDA Approval Path - StockTitan
NVNO Stock Touches 52-Week Low at $2.9 Amid Market Challenges - Investing.com
enVVeno launches recap website highlighting VEITH Symposium participation - TipRanks
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website - Kansas City Star
enVVeno Medical Showcases Breakthrough VenoValve Trial Data at VEITH Symposium | NVNO Stock News - StockTitan
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain - MSN
enVVeno Medical (NASDAQ:NVNO) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Reviewing enVVeno Medical (NASDAQ:NVNO) and Cerus (NASDAQ:CERS) - Defense World
PMA application submitted for VenoValve device - Venous News
enVVeno Medical (STU:5HJ) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
enVVeno Medical rises on submission of the venovalve PMA application for FDA approval - MSN
One-year data from the VenoValve US pivotal trial emerge - Venous News
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium - AccessWire
enVVeno Medical's VenoValve Trial Shows 85% Success Rate in Pivotal Study | NVNO Stock News - StockTitan
enVVeno Medical seeks FDA approval for VenoValve - Investing.com India
enVVeno Medical seeks FDA approval for VenoValve By Investing.com - Investing.com Canada
enVVeno Medical submits VenoValve PMA application to FDA - TipRanks
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval - AccessWire
enVVeno Medical Submits Final FDA Module for VenoValve Breakthrough Device | NVNO Stock News - StockTitan
Deep Venous Disease Treatment Devices Market 2024-2031 - openPR
Perceptive Advisors LLC's Strategic Acquisition in enVVeno Medical Corp - GuruFocus.com
enVVeno Medical (FRA:5HJ) Cyclically Adjusted FCF per Share : €0.00 (As of Jun. 2024) - GuruFocus.com
enVVeno Medical expects capital to fund company through several milestones - TipRanks
enVVeno Medical reports Q3 EPS (35c) vs. (45c) last year - TipRanks
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year - AccessWire
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
enVVeno Medical initiates six-month pre-clinical GLP study of enVVe - TipRanks
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R) - AccessWire
Comparing enVVeno Medical (NASDAQ:NVNO) and Accuray (NASDAQ:ARAY) - Defense World
NVNO Stock Hits 52-Week Low at $3.06 Amid Market Challenges - Investing.com UK
Contrasting enVVeno Medical (NASDAQ:NVNO) and Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Do investors need to be concerned about enVVeno Medical Corporation (NVNO)? - US Post News
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session - MSN
Finanzdaten der Envveno Medical Corporation-Aktie (NVNO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
0.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):